Randomized trial · people

Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trial

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, retatrutide cut liver fat sharply within 24 weeks in people with fatty liver disease, with larger cuts in the higher-dose arms.

Kind
Randomized trial
Studied in
People
Number studied
98
Published
2024
Journal
Nat Med

What they tested

The team tested how much retatrutide changed liver fat after 24 weeks in people with fatty liver disease, compared with placebo.

How the study was done

A randomized, double-blind, placebo-controlled phase 2a substudy of 98 people from a larger obesity trial who had MASLD (metabolic dysfunction-associated steatotic liver disease, a fatty liver disease) and liver fat of at least 10%. They got weekly injections under the skin of retatrutide (1, 4, 8 or 12 mg) or placebo (a dummy shot) for 48 weeks, with the main result at 24 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 24 weeks, average liver fat changed by -42.9% in the 1 mg arm, -57.0% in the 4 mg arm, -81.4% in the 8 mg arm and -82.4% in the 12 mg arm, against +0.3% on placebo (all P < 0.001 versus placebo). Liver fat dropped into the normal range (under 5%) for 27%, 52%, 79% and 86% of people in those arms, and for 0% on placebo. Bigger drops in liver fat went along with changes in body weight, belly fat, and metabolic measures linked to better insulin sensitivity and fat handling.

What it doesn’t show

This is a substudy of a larger obesity trial with 98 people, and its main result comes at 24 weeks. It measured liver fat, not longer-term liver health outcomes.

The paper

Sanyal et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo